Neurocrine Biosciencesvs.United Therapeutics
NBIX vs UTHR · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
United Therapeutics is about 1.4× larger than Neurocrine Biosciences by market cap; United Therapeutics trades at the lower P/E (17.0 vs 22.0).
Side by side
| NBIX | UTHR | |
|---|---|---|
| Market cap | $15.5B | $22.3B |
| Price | $153.37 | $518.53 |
| Today | +0.2% | +1.1% |
| Return YTD | +7.9% | +5.3% |
| Return 1Y | +13.0% | +64.3% |
| P/E | 22.0 | 17.0 |
| P/S | 4.6 | 7.1 |
| P/B | 4.2 | 3.5 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →United TherapeuticsUTHR
Pulmonary hypertension accounts for the marketed drugs, Tyvaso, Remodulin and Orenitram among them. A separate programme works on organs for transplant, including xenotransplantation.
Full UTHR profile →More NBIX & UTHR comparisons
Other head-to-heads in the Biotech & innovation segment.
See where NBIX and UTHR sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →